{"entity":{"id":"cd80","kind":"target","name":"CD80 (B7-1)","aka":["B7-1","B7.1","CD28LG","CD80 molecule"],"tldr":"B7-1 is a molecule on antigen-presenting cells that gives T cells their go signal through CD28, but it also feeds the CTLA-4 brake and can pair with PD-L1. Anti-PD-L1 antibodies such as sugemalimab and adebrelimab are built to stop PD-L1 binding both PD-1 and B7-1.","summary":"CD80 (chromosome 3q13.33), also called B7-1, is an immunoglobulin-superfamily costimulatory ligand that acts as the primary auxiliary signal for naive T cells by binding CD28, activating NF-kappa-B and MAPK and raising cytokine production and, through PI3K/AKT, T-cell glucose metabolism; it also binds CTLA-4, a decoy receptor that blocks CD28-mediated priming, and regulates PD-L1/PD-1 interactions (UniProt P33681). In OnCo it appears in the mechanism of the PD-L1 antibodies adebrelimab and sugemalimab, which block PD-L1 binding to PD-1 and to B7-1, and in the mechanism of ipilimumab, which stops CTLA-4 from outcompeting CD28 for B7 ligands during priming.","asOf":"2026-09-22","links":[{"label":"HGNC HGNC:1700","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1700"},{"label":"UniProt P33681","url":"https://www.uniprot.org/uniprotkb/P33681/entry"},{"label":"NCBI Gene 941","url":"https://www.ncbi.nlm.nih.gov/gene/941"}],"tags":["wave5-target"],"related":["adebrelimab","sugemalimab","tqb2450","ipilimumab","cd28","ctla4","pdl1"],"cancers":["sclc","nsclc","peripheral-t-cell-lymphoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["pd1-checkpoint","cancer-immunity-cycle"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded in this wave: HGNC and UniProt carry no positivity rates and no other source was consulted."],"provenance":{"editedBy":"OnCo content wave 5 (HGNC REST, UniProt REST, corpus drug and pathway records)","editedOn":"2026-09-22"},"symbol":"CD80","hgnc":"HGNC:1700","ensembl":"ENSG00000121594","uniprot":"P33681","entrez":"941","biology":"The same ligand serves an accelerator (CD28) and a brake (CTLA-4), which is why CTLA-4 blockade increases T-cell priming. PD-L1 antibodies that also free B7-1 restore CD28 costimulation as well as lifting the PD-1 brake.","whereFound":["Dendritic cells, macrophages and activated B cells","Small-cell lung cancer (adebrelimab) and NSCLC and peripheral T-cell lymphoma (sugemalimab) populations"],"targetClass":"checkpoint","prevalence":[]},"route":"/targets/cd80/","neighbours":{"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"sugemalimab","kind":"drug","name":"Sugemalimab","route":"/drugs/sugemalimab/"},{"id":"tqb2450","kind":"drug","name":"TQB2450","route":"/drugs/tqb2450/"}],"target":[{"id":"cd28","kind":"target","name":"CD28","route":"/targets/cd28/"},{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"pathway":[{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/"},{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/"}]}}